Regenerative Medicine Company Vascudyne Closes $ 10 Million Series A Funding
Stillwater, MN – News Direct – Vascudyne, Inc.
The investment will support expanded clinical trials of TRUE Graft, establish a commercial GMP manufacturing facility, and further develop TRUE Tissue platform technology for additional products.
Vascudyne, Inc., a biotechnology pioneer in regenerative medicine, today announced that it has raised $ 10 million in Series A cash through a global group of investors.
In July, Vascudyne also announced the success first human use of TRUE ™ Graft for access to hemodialysis in patients with end stage renal disease. The early product developments and preclinical studies of Vascudyne were funded by angel investors. Since its incorporation, Vascudyne has transferred regenerative technology, vertically integrated manufacturing and launched the first human clinical trial of TRUE Graft.
Vascudyne TRUE to Nature ™ biomaterials are unique and 100% natural. While other regenerative medicine cardiovascular devices contain scaffolds made from synthetic polymers that slowly break down in the body and can lead to an unwanted immune response, the TRUE ™ fabric the technology is 100% organic: nothing synthetic or artificial is ever used in the manufacturing process.
“We are delighted that investors are sharing our passion to bring our TRUE Tissue platform technology to patients around the world,” said Rick Murphy, vice president of operations and general manager of Vascudyne. “We are developing our BPF manufacturing facility to support the expansion of the clinical safety study of our TRUE Graft for access to hemodialysis and to accelerate the clinical use of new products that are currently under development for more. multiple cardiovascular applications. “
“The closing of the Serie A round is a very exciting step for Vascudyne,” said Kem Schankereli, CEO of Vascudyne. “We are building momentum and leading the way so that we can deliver our TRUE tissue regeneration material technology to patients in need. Series A funding provides the support needed to grow the organization so that we can continue our clinical trials, expand our operations, and translate additional products using our TRUE technology platform, from preclinical to clinical trials. . “
Vascudyne authorized its proprietary TRUE Tissue technology developed by world leader in tissue engineering Robert Tranquillo, PhD, Distinguished Professor at McKnight University, and his colleagues at the University of Minnesota in 2017.
TRUE Graft is not available for commercial sale.
Based in the heart of Medical Alley, Minnesota, Vascudyne’s mission is to improve patient care with regenerative biomaterials inspired by nature. Vascudyne, a privately held company founded in 2014, uses TRUE ™ Tissue technology to develop TRUE to Nature ™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/.
About TRUE Tissue Technology
TRUE ™ Tissue is developed from cells isolated from donor tissue and is 100% organic. There are no synthetic or chemical fixation materials used, and the implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be easily shaped into tubes, sheets and other geometries, making it suitable for many soft tissue applications, is mechanically comparable to native tissue, and is a ready-to-use allograft.
This announcement contains forward-looking statements. Such statements may include, but are not limited to, statements identified by words such as “plans”, “may”, “will”, “could”, “should”, “should”, “believe”, “s ‘expects to’, ‘plans’, ‘estimates’, ‘intentions’, ‘plans’, ‘potential’ or similar expressions. These statements relate to future events or to Vascudyne’s clinical development programs, reflect the current beliefs and expectations of management, and involve known and unknown risks, uncertainties and other factors that may cause results, performance or significantly different actual achievements of Vascudyne. Vascudyne assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Sandy Williams, Marketing Director
See the source version on newsdirect.com: https://newsdirect.com/news/regenerative-medicine-company-vascudyne-closes-10-million-series-a-financing-526027886